BridgeBio looks set to challenge BioMarin’s monopoly in treating restricted growth in children with achondroplasia after generating promising Phase II data from its candidate infigratinib.
Bridgebio Ready To Challenge BioMarin In Achondroplasia
The company sees a $5bn opportunity to treat children with achondroplasia and the less severe growth disorder variant, hypochondroplasia.
